Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706394 | 0.92 | SLC6A9 (0.49) | SLC6A9GPR119MGLLKCNH2USP30 | |
| SCHEMBL5662800 | 0.86 | HRH3 (0.37) | SLC6A9GPR119MGLLUSP30HRH3 | |
| SCHEMBL5663752 | 0.86 | SLC6A9 (0.42) | SLC6A9GPR119KCNH2KDM1A | |
| SCHEMBL4757473 | 0.86 | ACACB (0.44) | HRH3 | |
| SCHEMBL14437322 | 0.85 | SLC6A9 (0.43) | SLC6A9GPR119KCNH2USP30 | |
| SCHEMBL4827676 | 0.85 | SLC6A9 (0.43) | SLC6A9GPR119KCNH2USP30 | |
| SCHEMBL4756953 | 0.84 | ACACB (0.46) | — | |
| SCHEMBL5663754 | 0.82 | SLC6A9 (0.41) | SLC6A9GPR119KCNH2 | |
| SCHEMBL4706419 | 0.80 | SLC6A9 (0.44) | SLC6A9HRH3KDM1A | |
| SCHEMBL4705699 | 0.78 | SLC6A9 (0.40) | SLC6A9HRH3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | claimed |
| EP-1979318-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007089683-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089683-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, HSD17B11, CYP11B1 | SLC6A9 2932/4885GPR119 605/4885MGLL 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.